328 related articles for article (PubMed ID: 31907250)
1. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
[TBL] [Abstract][Full Text] [Related]
3. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
[TBL] [Abstract][Full Text] [Related]
4. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
5. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
7. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
8. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M; Valle J; Paulukonis S; Holl JL; Tanabe P; French DD; Garg R; Liem RI; Badawy SM; Treadwell MJ
Pediatr Blood Cancer; 2020 May; 67(5):e28152. PubMed ID: 32147964
[TBL] [Abstract][Full Text] [Related]
9. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
10. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
11. Increased Patient Activation Is Associated with Fewer Emergency Room Visits and Hospitalizations for Pain in Adults with Sickle Cell Disease.
Cronin RM; Dorner TL; Utrankar A; Allen W; Rodeghier M; Kassim AA; Jackson GP; DeBaun MR
Pain Med; 2019 Aug; 20(8):1464-1471. PubMed ID: 30329108
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
13. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
14. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012.
Gondhi JP; Dombkowski KJ; Scott EL; Reeves SL
J Pediatr; 2020 Sep; 224():79-86.e2. PubMed ID: 32446724
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
18. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.
Zumberg MS; Reddy S; Boyette RL; Schwartz RJ; Konrad TR; Lottenberg R
Am J Hematol; 2005 Jun; 79(2):107-13. PubMed ID: 15929107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
